Publication:
Erratum: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis (British Journal of Clinical Pharmacology (2000) 49 (445-452))

dc.contributor.authorB. J. Angusen_US
dc.contributor.authorM. D. Smithen_US
dc.contributor.authorY. Suputtamongkolen_US
dc.contributor.authorH. Mattieen_US
dc.contributor.authorA. L. Walshen_US
dc.contributor.authorV. Wuthiekanunen_US
dc.contributor.authorW. Chaowagulen_US
dc.contributor.authorN. J. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherLeiden University Medical Center - LUMCen_US
dc.contributor.otherSappasitthiprasong Hospitalen_US
dc.date.accessioned2018-09-07T09:24:02Z
dc.date.available2018-09-07T09:24:02Z
dc.date.issued2000-01-01en_US
dc.description.abstractAims. Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta-lactam antibiotics for serious Gram-negative infections. Severe melioidosis (Burkholderia pseudomallei infection) carries a mortality over 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis. Methods. Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg-18 hourly by bolus injection or 4 mg kg-1h-1by constant infusion following a 12 mg kg-1priming dose and pharmacokinetic and pharmacodynamic parameters were compared. Results. Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC90of B. pseudomallei was 2 mg l-1, giving a minimum target concentration (4*MIC) of 8 mg l-1. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half-lives of ceftazidime were 0.468 (0.241-0.573) l kg-1, 0.058 (0.005-0.159) l kg-1h-1and 7.74 (1.95-44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (r = 0.71; P < 0.001) and there was no evidence of significant nonrenal clearance. Conclusions. Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure, which is common in patients with meliodosis is Clearance = k* creatinine clearance where k = 0.72. Calculation of a loading dose gives median (range) values of loading dose, D(L) of 18.7 mg kg-1(9.5-23) and infusion rate I = 3.5 mg kg-1h-1(0.4-13) (which equals 84 mg kg-1day-1). A nomogram for adjustment in renal failure is given.en_US
dc.identifier.citationBritish Journal of Clinical Pharmacology. Vol.50, No.2 (2000), 183-191en_US
dc.identifier.issn03065251en_US
dc.identifier.other2-s2.0-0033865366en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/26340
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033865366&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleErratum: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis (British Journal of Clinical Pharmacology (2000) 49 (445-452))en_US
dc.typeErratumen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033865366&origin=inwarden_US

Files

Collections